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Abstract 
Anxiety is one of the most prevalent mood disturbances in the United States. The 
underlying genetic and neural bases of anxiety are complex, but previous research 
suggests that anxiety may be associated with alterations in brain structures, such as the 
hippocampus, and with genetic variations within genes like that of the Brain Derived 
Neurotrophic Factor (BDNF). To try to better understand these factors, we examined 
hippocampal volume, BDNF genotype, and self-report measures of anxiety together in a 
single study. We hypothesized that individuals with the Met allele of the BDNF gene 
would have reduced hippocampal volumes and elevated anxiety scores relative to 
individuals with the Val/Val genotype. This hypothesis was not well supported by the 
data. Implications for understanding the genetic and neural bases of anxiety are 
discussed.  
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Introduction 
 
 Anxiety disorders are among the most common mood disorders in the United 
States, affecting approximately 18% of adults aged 18 and older annually, yet the origins 
of anxiety are still largely a mystery (National Institute of Mental Health, 2002). The 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) recognizes over ten 
different types of clinically relevant anxiety disorders, the most common of which 
include generalized anxiety disorder (GAD), simple phobia disorder, obsessive-
compulsive disorder (OCD), panic disorder, and post-traumatic stress disorder (APA, 
2000). These conditions can differ extensively in their presentation of symptoms, but at 
the most general level, anxiety is characterized by marked uncertainty, fear and 
uneasiness, as well as uncontrollable repetitive thoughts that activate feelings of panic 
and inhibit the ability to stay calm. When left untreated, anxiety disorders can often 
develop into more persistent conditions with poorer treatment outcomes, or may become 
comorbid with other mood disorders including major depressive disorder (National 
Institute of Mental Health, 2002). Additionally, many of the symptoms of anxiety can be 
experienced in a more mild range within otherwise psychologically healthy individuals, 
which is classified as subclinical anxiety, but nevertheless can have substantial effects on 
cognition, sleep and mood (Ng, Chan, & Schlaghecken, 2012; Spira et al., 2008).  
Although there is still considerable debate as to the specific mechanisms 
underlying anxiety disorders, a genetic link has been identified that may predispose 
individuals to higher rates of anxiety. Specifically, many studies have looked at the brain-
derived neurotrophic factor protein, which is more commonly referred to as BDNF, and 
is coded for by the BDNF gene. Within the brain, BDNF is a prominent neurotrophin-
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signaling molecule that is vital to the differentiation, growth and survival of neurons. It is 
found throughout the cortex but is abundant in areas of the limbic system such as the 
hippocampus and amygdala, which are both involved in executive functions, including 
memory formation and emotion control (Huang & Reichardt, 2001). BDNF displays a 
single nucleotide polymorphism at codon 66 that results in a Valine to Methionine 
substitution known as the Val66Met polymorphism (Appendix A).  
The Val66Met polymorphism has been shown to influence several attributes in 
humans including hippocampal volume, memory performance and anxiety-related traits 
(Hajek, Kopecek, & Höschl, 2012; Jiang et al., 2005; Szeszko et al., 2005). Pertinent to 
this investigation, individuals with the Met allele of the BDNF gene show a reduced 
volume of the hippocampal formation compared to Val/Val individuals (Bueller et al., 
2006; Hajek et al., 2012; Montag, Weber, Fliessbach, Elger, & Reuter, 2009; Pezawas et 
al., 2004; Szeszko et al., 2005; Yang et al., 2012). Additionally, the Val66Met 
polymorphism may be a risk allele for the development of anxiety as some argue that the 
Met allele is implicated in increased anxiety-related traits (Chen et al., 2006; Hashimoto, 
2007; Jiang et al., 2005). However, others have argued the opposite, that the Val allele is 
more of a risk allele for increased anxiety (Lang et al., 2005) 
The volume of the hippocampus is an important neurological element of anxiety 
to investigate because the hippocampus is a major component of the limbic system, and is 
most well known for its role in emotion and the formation of memory (Appendix B). It is 
also more subject to stress-related changes than any other area of the brain (Woon, Sood, 
& Hedges, 2010). This is due to the fact that the hippocampus has a high level of 
glucocorticoid receptors to which stress hormones, such as cortisol, bind. With abnormal 
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levels of stress or longer durations of stress exposure, the excitability of some 
hippocampal neurons may be decreased, which can lead to increased cell death and 
eventual atrophy of the brain region itself (Joëls, 2009). For this reason, patients with 
mood disorders, such as anxiety and depression, tend to have reduced hippocampal grey 
matter volume (Bremner & Narayan, 2000; Campbell & Marriott, 2004; Sheline, Gado, 
& Kraemer, 2004).  
Some investigations have explored the relationship between hippocampal grey 
matter volume and anxiety-related traits, with conflicting results. That is, some studies 
have found a positive correlation between hippocampal volume and anxiety, with higher 
anxiety being associated with larger hippocampi (Baur, Hänggi, & Jäncke, 2012; Rusch, 
Abercrombie, Oakes, Schaefer, & Davidson, 2001). Others have found the opposite, with 
higher anxiety and depression associated with smaller hippocampal structures (Campbell 
& Marriott, 2004; Kalisch et al., 2006; Kühn, Schubert, & Gallinat, 2011).  
The evidence of the distinct associations between genes and anxiety, genes and 
hippocampal volume, and hippocampal volume and anxiety, naturally leads to the 
investigation of how all three variables interact together. Previous studies have looked at 
the relationship between all three variables (Montag et al., 2009), but none have focused 
solely on healthy participants and their subjective experience of anxiety symptoms as 
they relate to BDNF genotype and hippocampal volume. Such an investigation is 
essential to understanding the relationship between the genetic, structural, and behavioral 
components of sub-clinical levels of anxiety. The purpose of this study is to investigate 
how a genetic polymorphism within the BDNF gene may lead to differences in 
hippocampal volume and vulnerability to anxiety. 
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Therefore, the present study examines the nature of the relationship between three 
variables: BDNF polymorphism, subjective anxiety scores, and regional hippocampus 
volumes, to obtain a more comprehensive understanding of how all three variables may 
interact and influence one another. This study will address three distinct hypotheses: 1. 
The Met allele will be associated with a reduction in hippocampal volume, 2. Individuals 
with this reduction in hippocampal volume will show an increase in anxiety symptoms, 
and 3. Carriers of the Met allele will have higher anxiety.  
 
Methods 
Participants 
 Sixty-two healthy University of Colorado undergraduate students (33 males; 
53.2%) from the department of Psychology and Neuroscience participated for course 
credit or payment. All participants had no history of previous psychiatric diagnoses or 
medication. Informed consent was acquired according to the guidelines of the 
Institutional Review Board of the University of Colorado at Boulder. The final sample 
included two groups, Met+ (N=21 (Met/Val N=20, Met/Met=1); 52% male; Age: 
M=19.43; SD=1.5) and Val/Val (N=41; 54% male; Age: M=20.29; SD=6.31). The two 
groups did not differ in age (p>.5) or gender (p>.9). 
 
Procedure 
Participants first came to the Cognitive Development Center to complete a self-
report questionnaire measuring symptoms related to anxiety, and to provide a saliva 
sample used to identify their individual genotype. After this data was collected and 
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analyzed, subjects were invited to participate in the second phase of the study in which an 
fMRI brain scan was used to obtain brain-imaging data for VBM analysis of hippocampal 
volumes.  
 
Genotyping 
 All subjects provided a 3mL saliva sample, which was analyzed for BDNF alleles 
at The Children’s National Medical Center in Washington D.C. The Met and Val alleles 
were identified at codon 66 of chromosome 11. Genotype frequencies were in Hardy-
Weinberg equilibrium (X2= .688, df= 2, P>.7).  
 
Self-Report Anxiety Measurement 
The State-Trait Anxiety Inventory for Adults (STAI) was used to obtain a 
measurement of self-reported anxiety (Spielberger, 1970). The inventory consists of two 
scales with 20 questions each and is intended to measure current (state) anxiety and 
longer-term (trait) anxiety in adults (Spielberger, 2005). The STAI is used to evaluate 
feelings such as worry, apprehension, and nervousness. For the “state” score, participants 
were asked to respond to a particular sentiment in terms of how strongly they feel that 
emotion in that moment. For example, one statement is “I feel calm” and participants can 
respond with 1indicating  “not at all”, 2 being “somewhat”, 3 being “moderately so”, or 4 
being “very much so”. For the “trait” score, they are asked to respond to a statement with 
how often they feel that statement in general. For example, the statement “I feel pleasant” 
can have a response of 1 indicating “almost never”, 2 being “sometimes”, 3 being 
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“often”, and 4 being “almost always”. Scores range from 20 to 80 on each scale, with a 
higher score indicating elevated levels of state or trait anxiety.  
The raw score on both the state and trait inventories were translated into a 
percentile score using the guidelines of the STAI manual (Spielberger & Vagg, 1984). 
Percentile scores indicate the standardized rank of anxiety traits among undergraduate 
college students as a whole. The percentile scores for both state and trait anxiety were 
thus the primary source of data used in this study to measure and represent relative 
anxiety within the undergraduate population. Overall, we were most interested in the trait 
measure of anxiety as it best represents an individual’s stable anxiety level as well as 
differences in response intensity to psychological stress among people. Due to copyright 
laws, we are unable to provide the STAI in an appendix.  
 
MRI and VBM analysis 
 Voxel Based Morphometry (VBM) analyses were performed using FSL software 
and the processing procedure followed that established by Ashburner et al. (2000) and 
Good et al. (2001). VBM is a technique of neuroimaging in which the volumes of 
different brain areas are calculated and can then be compared, both within and between 
groups. This technique relies on structural brain images, which are obtained through 3D-
MPRAGE scans conducted within a functional MRI scan. After a brain scan from all 
participants was collected, the images were normalized, and the grey matter was 
extracted using the FSL default BET brain extraction process, to strip the skull and 
remove non-brain tissue from the image using the FAST4 tool. This results in grey matter 
images that are then aligned to MNI152 standard space using the affine registration tool 
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FLIRT (FMRIB’s Linear Image Registration Tool) and then the nonlinear registration 
tool using FNIRT (FMRIB’s Nonlinear Image Registration Tool). A study-specific 
template is then made from averaging all of these images and then non-linearly re-
registering the original grey matter images using FNIRT. To correct for possible local 
expansion and contraction, the registered partial volume images were modulated by 
dividing the Jacobian of the warp field. This results in modulated segmented images that 
are then smoothed by an isotropic Gaussian kernel with a sigma of 3, resulting in full-
width half-maximum (FWHM) of 3x2.3mm=6.9mm. Using permutation-based, non-
parametric testing with Monte Carlo simulations, voxelwise thresholding is applied 
which corrects for multiple comparisons. Finally, clusterwise correction is applied using 
the built-in cluster-based thresholding technique in FSL’s VBM toolbox. (Ashburner & 
Friston, 2000; Good et al., 2001; Smolker, Depue, Reineberg, & Banich, in progess). 
 Through this process, every brain is compiled and normalized onto a template, 
which represents an average of all the volumes of each brain while also getting rid of 
some of the bigger differences in brain anatomy among people. When the brain images 
are smoothed, each voxel (or 3-D pixel) represents a volumetric average of itself and all 
of the voxels that surround it. From these measurements, volume can then be compared 
across brains at each voxel in order to determine small areas where volumes differ 
between groups. Total volume measurements can also be obtained, but in identifying an 
overall measure of an area, smaller more specific differences can often be overlooked. 
Masks may be drawn to narrow down analysis on one specific area of the brain, in this 
case the hippocampus. In this study, measures of both total hippocampus volume as well 
as voxel-by-voxel analyses were used to help identify differences in hippocampus 
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volume; however, an emphasis was placed on variations in total hippocampus volume to 
investigate the more broad-based hypotheses as well as gain a more comprehensive 
generalization of hippocampus differences among people in relation to anxiety traits.  
 
Results 
1. BDNF genotype and hippocampus volume 
 There was no significant relationship between BDNF genotype and total 
hippocampus volume (t62)=1.470, p=0.147; Figure 1). However, in a voxel-by-voxel 
measurement, the Val/Val group showed significantly larger hippocampal grey matter 
volumes than the Met+ group in small regions of both right posterior hippocampus 
(t(62)=3.824, p=0.013; Figure 2) and left anterior hippocampus (t(62)=3.287, p=0.036; 
Figure 3). 
 
Figure 1. Effect of BDNF group on total hippocampus volume: Val/Val participants 
did not differ when compared to Met+ individuals in mean total hippocampal 
volumes. Error bars represent standard error. 
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Figure 2. Voxel–wise analysis of grey matter volume of right posterior 
hippocampus: The highlighted area represents the region that is significantly larger 
in Val/Val groups than Met+ groups. 
 
 
 
Figure 3. Voxel–wise analysis of grey matter volume of left anterior hippocampus: 
The highlighted area represents the region that is significantly larger in Val/Val 
groups than Met+ groups. 
 
 
2. Hippocampus volume and anxiety 
 No significant correlation was found between total hippocampus volume and trait 
anxiety (r(62)=.120, p=0.353; Figure 4) or state anxiety (r(62)=.104, p=.421). 
Additionally, there was no significance between the right posterior hippocampal region 
and trait anxiety (r(62)=.159, p=.216, Figure 5) or the left anterior region and trait anxiety 
(r(62)=.132, p=.306 Figure 6).  
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Figure 4. Relationship between total hippocampus volume and trait anxiety: 
Hippocampus volume does not significantly predict anxiety score. 
 
 
 
Figure 5. Relationship between volume of right posterior hippocampus region and 
trait anxiety: Volume of right posterior hippocampus volume does not significantly 
predict anxiety. 
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Figure 6. Relationship between volume of left anterior hippocampus region and trait 
anxiety: Volume of left anterior hippocampus region does not significantly predict 
anxiety. 
 
 
3. BDNF genotype and anxiety 
 No significance was found between BDNF genotype and anxiety during the first 
phase of the study (Trait: t(62)=-1.353, p=0.181, Figure 7; State: t(62)=-.974, p=.334). 
However, during the second phase of the study at the time of fMRI scanning, the Met+ 
group showed lower state anxiety than the Val/Val group (t(52)=2.475, p=0.017; Figure 
8). 
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Figure 7. Effect of BDNF genotype on trait anxiety: Genotype group does not 
significantly predict anxiety. Error bars represent standard error. 
 
 
 
Figure 8. Effect of BDNF genotype on anxiety:  The Met+ group showed 
significantly lower state anxiety than the Val/Val group at the time of fMRI 
scanning. Error bars represent standard error. 
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4. BDNF genotype by total hippocampus volume interaction 
 Overall, the interaction of BDNF genotype and total hippocampus volume was 
not significantly related to trait anxiety (r(62)=0.035, p=0.785). Additionally, no 
significant relationship was found within individual BDNF genotype groups of total 
hippocampus volume on trait anxiety (Val/Val: r(62)=0.720, p=0.580; Met+: 
r(62)=0.089, p=.235, Figure 9).  
 
  
Figure 9. Effect of Hippocampus Volume X BDNF interaction on trait anxiety: 
Interaction of hippocampus volume and BDNF genotype does not significantly 
predict anxiety.  
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5. BDNF genotype by total hippocampus volume group interaction 
To further explore this interaction, one other approach was taken whereby each 
participant’s total hippocampus volume was categorized into either “high” or “low” 
volume categories depending on if it was above or below the average volume for all 
participants. The hippocampus volume and genotype classifications were then combined 
and the effect of group on anxiety was noted. The interaction was not significant for trait 
anxiety (t(62)= -1.498, p=0.139, Figure 10), although the groups show an interesting, 
opposing pattern depending on genotype. That is, individuals with the Val/Val genotype 
and a low hippocampus volume classification exhibited the most anxiety whereas the 
Met+ carriers with a low hippocampus volume classification exhibited the lowest levels 
of anxiety. 
 
 
Figure 10. Effect of BDNF genotype X hippocampus volume group designations: 
BDNF by hippocampus group interaction does not significantly predict anxiety 
though relationships are opposing depending on genotype group.  
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Discussion 
 Overall, the hypothesized correlations between BDNF genotype and hippocampal 
volume, hippocampal volume and anxiety, and BDNF and anxiety were not strongly 
supported by the current study’s data. BDNF genotype is not a significant predictor of 
total hippocampus volume, however, there are significant voxel-wise differences between 
the two groups with the Met+ group showing smaller areas of bilateral hippocampi than 
Val/Val. BDNF genotype is also not a significant predictor of anxiety, but there is a 
general tendency of the Met+ group showing lower anxiety than the Val/Val group. This 
difference is only significant in state measures of anxiety at the time of fMRI scanning. 
Finally, total hippocampus volume is not a significant predictor of anxiety score in either 
measure of anxiety.  
Additionally, the interaction of BDNF genotype and hippocampus volume does 
not significantly predict anxiety. However, the interaction of BDNF genotype group and 
hippocampus volume group shows an opposing pattern between genotypes whereby a 
low hippocampus volume in Met+ individuals may be protective against higher levels of 
anxiety, while a low hippocampus volume in the Val/Val category may be unfavorable 
and increase vulnerability to higher levels of anxiety.  
Many limitations were present that could have had an effect on significance 
between variables. For one, the sample size may have been too small to see notable 
differences between groups, especially in the independent sizes of genotype groups. 
Regardless of population size, this investigation is still limited in the sense that the 
difference in BDNF processing between Met and Val alleles may not yet be well 
understood. That is to say, our interpretation of the dampened BDNF processing of Met+ 
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alleles may not be as unfavorable in terms of hippocampus volume or anxiety as we 
suspect it is. Perhaps the decrease in activity-dependent BDNF secretion seen in the Met+ 
group is not an entirely defective molecular process but rather a more fine-tuned one, 
resulting in a reduced need for neurogenesis, as shown by the trend of the Met+ group 
showing smaller hippocampus structures. 
 Similarly, if a more efficient process such as this were actually the case, then it 
would seem intuitive that the Met+ group displays less anxiety than the Val/Val group as 
suggested by some investigations (Lang et al., 2005; Sen et al., 2003). One study in 
particular investigated serum BDNF concentrations in humans and found that in Val/Val 
participants, BDNF serum concentrations were lower but risk of having an episode of 
major depression was increased (Lang, Hellweg, Sander, & Gallinat, 2009). Additionally, 
studies have looked into the phenomenon of the Val allele being preferentially 
transmitted more so in families with histories of depression or bipolar disorder, thereby 
possibly increasing the co-occurrence of Val/Val genotypes and difficult mood disorders 
(Neves-Pereira et al., 2002; Sklar et al., 2002). Both of these ideas give further support to 
the notion that what we know about the individual Met and Val allele processes may not 
encapsulate the entirety of the effect they have on anxiety. 
Furthermore, there is a possibility that teasing apart clinical and subclinical 
anxiety more finely would aid in understanding the cellular and molecular differences at 
work. For instance, some postulate that higher state anxiety is not necessarily an 
indication of higher situational subclinical anxiety traits, but rather a risk factor for major 
depressive disorder, being that depressive disorders are typically state dependent (Sklar et 
al., 2002). In a similar way, others suspect that trait anxiety may not be an accurate 
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reflection of anxiety-related traits but also depression-related traits since depression and 
sub-threshold anxiety symptoms are often comorbid (Silverstone & Von Studnitz, 2003). 
In either case, the takeaway is that subclinical anxiety is difficult to accurately measure 
on its own without further confounds from clinical symptoms. In addition, the molecular 
and physiological underpinnings of anxiety may operate differently when symptoms do 
not meet criteria for clinical diagnosis. For instance, recent evidence suggests that 
hyperactivation of the hippocampal-amygdala network may be more of an indication of 
elevated subclinical anxiety symptoms which cannot be deduced by just the size of either 
area on its own (Blackmon, Barr, & Carlson, 2011; Laeger et al., 2012). 
In line with this idea of other brain mechanisms at work in subclinical anxiety 
traits, is the question of what mechanisms can actually be inferred by the grey matter 
volume of the area in question, and what the size of the hippocampus actually tell us. The 
implicit assumption behind many past morphological studies, as well as this one, is that a 
decrease in size must indicate and decrease in function, however, that may be far from 
the case. Especially when trying to associate a complex behavior such as anxiety with a 
brain region that carries out multiple functions, relative brain volume may not have the 
answers that we expect it to and, even further, any significant correlations must be 
approached delicately as they may not imply any degree of causation (Healy & Rowe, 
2007). In addition, the hippocampus is one of the few structures of the brain that has the 
ability to vary in size throughout life and, moreover, gradually decreases in size with age 
(Erickson et al., 2011). This means that, at any point during the lifespan, the grey matter 
volume of the hippocampus has the potential to be implicated in a number of behavioral 
relationships, all of which may not be entirely conclusive.  
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In general, smaller hippocampus size has been linked to elevated stress levels, but 
as our data demonstrates, this might not always be the case being that the group that had 
higher levels of anxiety in our sample (Val/Val) also showed larger hippocampal 
structures. As exemplified by the interaction of BDNF genotype and total hippocampal 
volume, the Met+ and Val/Val groups appear to work in different ways. Continuation of 
morphological and genetic studies in association with complex behaviors will be 
necessary to broaden the current understanding of the insight truly gained from these 
factors. Not only will it be imperative in understanding the meaning of grey matter 
volume and molecular genetic processes, but also of maladaptive behavior in order to 
better treat, control and manage complex behavior traits such as anxiety.  
The limitations of the current study could potentially be minimized by continued 
research in several subject areas. The first would be to understand and maintain a 
consistent difference in symptomology between subclinical anxiety and clinically 
significant anxiety disorders such that continued research into the genetic, molecular, 
cellular, and structural foundations of symptoms will help distinguish clinical treatment 
plans from everyday management of anxiety characteristics. In this way, more research 
into the difference in function of BDNF alleles may help to better individualize stress-
management strategies. Furthermore, the understanding of variation in hippocampal grey 
matter volumes could likely help distinguish between differing levels of anxiety both on a 
large scale as well as within separate BDNF polymorphism groups. Beyond these 
necessary areas of further exploration, critical information could likely be gained from 
examining other genes and/or brain areas that may be influential in the augmentation of 
anxiety features as well as interactions between and within these areas.  
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 By studying subclinical anxiety, we are seeking to understand the underlying 
genetic mechanisms and what molecular and cellular factors play important roles in 
contributing to the severity of anxiety symptoms. From this information, treatment 
methods may be better understood and developed to help correct for anxiety before it 
reaches a level worthy of clinical diagnosis. For example, with a better understanding of 
the underlying neuropathology of anxiety and the specific role of BDNF in anxiety, 
therapies and/or drug treatments could be tailored to individuals depending on BDNF 
genotype.  That is, if the neurotransmitter BDNF is found to be a major cause of anxiety, 
then it is possible that drug treatments may be helpful in blocking or increasing the 
neurotransmitter processing within the brain. Conversely, if inefficient generation of 
neurons (associated with reduced volume) within the hippocampus is found to be an 
important causal factor, therapies involving the stimulation and growth of neurons in 
these areas may prove to be extremely useful in treating anxiety. If both factors are found 
to play important roles, then treatment plans may need to find a way to integrate the two 
corrective approaches. Even more broadly, the information gained from this research can 
improve our biological and psychological understanding of levels of anxiety in healthy 
individuals with no diagnosis of anxiety disorders. In doing so, this data can provide a 
baseline of anxiety within a healthy population to then better recognize and understand 
abnormalities and deviations from this baseline.   
To summarize, this is a complicated picture with many caveats and various 
possible routes of interpretation. Continuing to investigate and pull apart different 
underlying neurobiological components of anxiety will be of great importance to 
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accomplishing the goal of this study as well as that of the overall attempt to understand 
and minimize anxiety, as well as better individualize treatment.  
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Appendix A 
 
The BDNF gene is located on chromosome 11 in humans, and like many other 
genes, displays a common and functional single nucleotide polymorphism (SNP), which 
simply means that the gene is present in more than one operational form and has multiple 
alleles. This type of polymorphism is the most common type of genetic variation among 
people, and describes an instance in which the DNA sequence of a gene differs by a 
single nucleotide—A, T, C or G. Oftentimes, this small change goes unnoticed because it 
either occurs outside of a coding region of a gene or has no effect on the amino acid 
produced from a specific codon (a set of three adjacent nucleotides that correspond to a 
particular amino acid in a polypeptide chain during DNA protein synthesis). The genetic 
code consists of 64 possible codons which each code for one of 20 amino acids. The 
genetic code is often described as redundant because of the fact that most amino acids 
can be coded for by more than one codon. Thus, the change in a single nucleotide of a 
codon can sometimes have no effect on the amino acid produced if two codons that differ 
by one nucleotide still code for the same amino acid. In other cases, though, a single 
nucleotide change can produce a range of differences in physiology depending on the 
function of the protein chain as well as the importance of the specific arrangement of the 
amino acids. A gene is said to have different alleles when there is an observed difference 
between different proteins coded for by the same gene due to genetic polymorphisms.   
In terms of BDNF, a common SNP occurs at codon 66, in which a single G 
nucleotide is replaced with an A nuclueotide and results in an amino acid substitution 
from Valine (Val) to Methionine (Met) more commonly known as Val66Met (Egan et al., 
2003). The Met allele of the BDNF SNP, while carried by only 30% of humans, and 
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therefore far less common than the Val allele, carries some important implications. Most 
notably, the Met allele contributes to defective activity-dependent secretion of BDNF in 
neurons. It does not alter the total level of BDNF within the brain, but rather impedes 
protein binding and processing (Frielingsdorf et al., 2010). The primary protein 
implicated in this change is sortillin, which is expressed in the cortex and hippocampus at 
high levels. Sortillin functions as a receptor for various ligands, including BDNF. More 
specifically, sortillin helps direct BDNF to neuronal secretory pathways where it may 
then respond to cellular depolarizations and be released to promote cell survival and 
synaptic plasticity (Evans et al., 2011). Therefore, the Met allele interferes with this 
cellular processing and generates lower depolarization-induced secretion in neurons and 
produces sub-optimal BDNF processing. This may, in turn, give rise to increased cell 
death or defective synaptic processing. Additionally, these effects are seen regardless of 
zygosity. That is, carriers of both a Met and a Val allele show the same dampened BDNF 
processing as individuals with two Met alleles. In most studies of BDNF, as in this one, 
Met carriers are studied as one group (Met+) and are compared to Val/Val individuals, 
rather than studying heterozygotes (i.e. Met/Val individuals) as a distinct and separate 
third group.  
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Appendix B 
Grey matter is an informative area of investigation in the field of 
neuropsychology because it is the major substantive component of the central nervous 
system and the brain in particular. The term ‘grey matter’ describes cerebral networks 
that appear grey as they are made up of specialized cells called neurons, which include 
neuronal cell bodies as well as their corresponding axons and dendrites. Neurons are not 
in direct contact with one another, so they communicate by way of chemical 
neurotransmitters such as BDNF. In contrast, white matter describes myelinated axon 
fibers that appear white, which help transmit messages to and from separate grey matter 
areas in the brain. While neurons are a type of cell, they do not undergo cell division but 
are rather generated by special types of stem cells in a process called neurogenesis. This 
process is most active during pre-natal and childhood development and largely ceases 
during adulthood, meaning that as neurons die, they are not regenerated. Recent evidence 
suggests, however, that the hippocampus is one of two areas of the brain within which 
new neurons are continually produced even throughout adulthood. Therefore, researchers 
have found that hippocampal neurogenesis in adulthood is one of the primary beneficial 
actions behind antidepressants in terms of reducing stress. That is, increased levels of 
neurogenesis are largely correlated with decreased levels of stress. This, in turn, means 
that the grey matter volume of this area may provide important information about the 
underlying mechanisms of stress processing and thus provide clues as to how to best 
manage stress at a cellular level.  
 
 
